Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation.
Animals
Antibodies, Monoclonal
/ chemistry
Antineoplastic Agents
/ chemical synthesis
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Depsipeptides
/ chemistry
Drug Screening Assays, Antitumor
Female
Humans
Hydrophobic and Hydrophilic Interactions
Immunoconjugates
/ drug effects
Mice
Mice, SCID
Molecular Conformation
Tumor Cells, Cultured
Journal
Organic & biomolecular chemistry
ISSN: 1477-0539
Titre abrégé: Org Biomol Chem
Pays: England
ID NLM: 101154995
Informations de publication
Date de publication:
21 09 2019
21 09 2019
Historique:
pubmed:
29
8
2019
medline:
4
3
2020
entrez:
29
8
2019
Statut:
ppublish
Résumé
We report a modular approach to synthesize maleimido group containing hydrophilic dolastatin 10 (Dol10) derivatives as drug-linkers for the syntheses of antibody-drug conjugates (ADCs). Discrete polyethylene glycol (PEG) moieties of different chain lengths were introduced as part of the linker to impart hydrophilicity to these drug linkers. The synthesis process involved construction of PEG maleimido derivatives of the tetrapeptide intermediate (N-methylvaline-valine-dolaisoleucine-dolaproine), which were subsequently coupled with dolaphenine to generate the desired drug linkers. The synthetic method reported in this manuscript circumvents the use of highly cytotoxic Dol10 in its native form. By using trastuzumab (Herceptin®) as the antibody we have synthesized Dol10 containing ADCs. The presence of a discrete PEG chain in the drug linkers resulted in ADCs free from aggregation. The effect of PEG chain length on the biological activities of these Dol10 containing ADCs was investigated by in vitro cytotoxicity assays. ADCs containing PEG
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Depsipeptides
0
Immunoconjugates
0
dolastatin 10
EI946JT51X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM